---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-25-000133"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:52:05.004252+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Centessa Q2 net loss $50.3M; cash $404.1M; ORX750 Phase 2a data on track for 2025

## Summary
- Net loss of $50.3M for Q2 2025, up from $43.8M in Q2 2024; R&D expenses rose to $42.7M.
- Cash, cash equivalents and investments totaled $404.1M as of June 30, 2025, expected to fund into mid-2027.
- ORX750 Phase 2a CRYSTAL-1 study ongoing; data in NT1, NT2, and idiopathic hypersomnia expected in 2025.
- ORX142 Phase 1 first-in-human trial initiated; data in sleep-deprived healthy volunteers expected in 2025.
- ORX489 in IND-enabling studies for neuropsychiatric disorders.

## SEC filing metadata
- accession: 0001847903-25-000133
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790325000133/0001847903-25-000133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790325000133/cnta-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-25-000133
- JSON: https://secwatch.observer/filing/0001847903-25-000133.json
- Plain text: https://secwatch.observer/filing/0001847903-25-000133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.